A newly characterized group of pharmacological compounds, when administered orally, blocks both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis (MS), revealed a study published in the journal Nature Neuroscience. Lead author Jeffery Haines at the Icahn School of Medicine at Mount Sinai said, "The multiple sclerosis drugs currently on the market and being tested elsewhere seek to reduce the immune attack on cells, but none of them ...
http://ift.tt/1vShGAG
http://ift.tt/1BWgEAm
No comments:
Post a Comment